Zogenix, Inc. (NASDAQ:ZGNX) Director Renee P. Tannenbaum purchased 5,000 shares of the firm’s stock in a transaction on Thursday, March 16th. The shares were acquired at an average cost of $11.00 per share, with a total value of $55,000.00. Following the completion of the acquisition, the director now directly owns 10,000 shares in the company, valued at $110,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Shares of Zogenix, Inc. (NASDAQ:ZGNX) traded down 1.40% during trading on Monday, reaching $10.55. The company had a trading volume of 196,430 shares. The stock’s market capitalization is $261.78 million. The stock has a 50 day moving average of $9.71 and a 200 day moving average of $10.38. Zogenix, Inc. has a 52-week low of $7.33 and a 52-week high of $13.70.

Your IP Address:

This article was originally published by and is the sole property of American Banking News. If you happen to be reading this article on another website, it was stolen and illegally republished in violation of U.S. and International copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/03/20/renee-p-tannenbaum-purchases-5000-shares-of-zogenix-inc-zgnx-stock.html

Several analysts have recently weighed in on the company. Aegis reissued a “buy” rating and issued a $28.00 target price on shares of Zogenix in a report on Saturday, March 11th. Zacks Investment Research downgraded Zogenix from a “buy” rating to a “hold” rating in a report on Wednesday, December 7th.

Several hedge funds have recently made changes to their positions in the stock. A.R.T. Advisors LLC acquired a new stake in shares of Zogenix during the fourth quarter valued at $154,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Zogenix during the third quarter valued at $169,000. City Financial Investment Co Ltd acquired a new stake in shares of Zogenix during the fourth quarter valued at $1,393,000. Bailard Inc. acquired a new stake in shares of Zogenix during the third quarter valued at $1,388,000. Finally, Senzar Asset Management LLC acquired a new stake in shares of Zogenix during the fourth quarter valued at $1,921,000. Institutional investors own 84.32% of the company’s stock.

Zogenix Company Profile

Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders in requirement of treatment alternatives. The Company’s areas of focus are epilepsy and schizophrenia.

5 Day Chart for NASDAQ:ZGNX

Receive News & Ratings for Zogenix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.